Abstract library

12 results for "Albertelli".
#432 Ten Years of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Evolution of Classification and Correlation with Follow-up in 50 Patients
Introduction: In the last decade, GEP-NET nomenclature has been twice reviewed. The 2000 WHO classification had poor prognostic power in well-differentiated (WD) neoplasms which led to the introduction of two new important parameters: grade and stage, by ENETS; the former became part of the new 2010 WHO classification.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Diego Ferone
#570 Lymph-Nodal Merkel Cell Carcinoma (MCC) in the Absence of Primary Tumor: Regression of the Primary or Lymph-Nodal Primitivity? Report of a Series with Favorable Prognostic Behavior
Introduction: MCC is a rare cutaneous neuroendocrine neoplasm with aggressive behavior, a high recurrence rate and, generally, poor prognosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Diego Ferone
#584 KI-67 HETEROGENEITY IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMORS
Introduction: The neuroendocrine tumor (NET) proliferation-based grading system (ENETs/WHO) has proved reliable for prognostic stratification, however concerns exist on Ki67 heterogeneity.
Conference:
Category: Basic
Presenting Author: Dr Federica Grillo
#587 First in vitro study of Human GastroEnteroPancreatic-Neuroendocrine Tumors: comparative effect of Octreotide, Pasireotide and Everolimus.
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference:
Category: Basic
Presenting Author: MD Manuela Albertelli
#752 First In Vitro Study of Human Gastroenteropancreatic Neuroendocrine Tumors: Comparative Effect of Octreotide, Pasireotide and Everolimus
Introduction: Recently pasireotide (PAS) and everolimus (RAD) emerged as potential therapies for neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Prof. Diego Ferone
#836 Grade Increases In Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor
Introduction: The neuroendocrine tumor (NET) proliferation-based grading system (ENETS/WHO) has proved reliable for prognostic stratification of gastroenteropancreatic tumors (GEP). Although anecdotes have been published, no single study has evaluated whether grade changes between primary site and metastases.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Prof Federica Grillo
#837 Does Biopsy Reliably Identify Grade In Gastroenteropancreatic Neuroendocrine Tumors?
Introduction: A new proliferation-based grading system has proved important in establishing prognosis and guiding therapy in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Biopsies are often performed for grading but little is known about their reliability in assigning grade.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Prof Federica Grillo
#1476 Efficacy of Everolimus and Somatostatin Analogs as Single Agents or in Combination in Human Pancreatic Neuroendocrine Tumors Primary Cultures
Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: doctor Corinne Gerard
#1538 Safety of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial
Introduction: Dose escalation (or interval reduction) of somatostatin analogs (SSAs) is a rather common strategy for patients (pts) with progressive metastatic neuroendocrine tumors (NETs). However, to date, no systematic prospective studies have been carried out to evaluate safety and efficacy of this treatment schedule in NETs.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD, PhD Manuela Albertelli
#1550 Very Early Response to Sunitinib in VHL Patient with Pancreatic Neuroendocrine Tumor
Introduction: Pancreatic neuroendocrine tumors (pNET) arise in 8-17% of Von Hippel Lindau (VHL) patients and surgery plays a key role for resectable lesions. Alternative medical therapy, such as target therapy (TT), can be used when surgery is unfeasible
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD, PhD Manuela Albertelli
Keywords: VHL therapy